Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 525 trials

Hidradenitis Suppurativa: IC0624 Treatment Study

We are testing a new medication, IC0624, for people with mild to moderate Hidradenitis Suppurativa. The study will help us understand its effects on symptoms, pain, and overall quality of life.

Hidradenitis Suppurativa≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesDermatology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Fertility Study: Metformin for Women Post-Thyroid Cancer

We are evaluating whether metformin can improve fertility in women treated with radioactive iodine for thyroid cancer. The study will look at hormone levels and ovarian health to see how effective the treatment is.

Papillary Thyroid Carcinoma1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesGynecology and ObstetricsOncology

Idiopathic Membranous Nephropathy: AP1189 Study

We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.

Membranous Nephropathy1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

STOP-LEUKEMIA: Metformin for Blood Disorders

We are investigating whether metformin can help prevent leukemia in patients with clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. This study will assess the safety of metformin and explore how it may affect disease progression.

Myelodysplastic Syndromes (MDS)Clonal Cytopenia of Undetermined Significance (CCUS)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Ischemic Stroke: Thrombolytic Therapy with rtPA

We are studying a new treatment for patients with acute ischemic stroke who are on blood thinners. The goal is to see if this therapy improves recovery compared to a placebo after reversing the blood thinner's effects.

Ischaemic Stroke3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Glaucoma: Oral Semaglutide Study

We are investigating whether oral semaglutide can safely improve retinal function in patients with open-angle glaucoma. This research may help find new ways to protect vision in those affected by this condition.

Glaucoma>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyOphthalmology

Advanced Non-Small Cell Lung Cancer: H1-Antihistamine with Immunotherapy

We are studying whether adding an H1-antihistamine to immunotherapy can improve treatment response in patients with advanced non-small cell lung cancer.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Acute Cholecystitis: Indocyanine Green in Surgery

We are testing whether indocyanine green can help reduce surgery time and improve safety during gallbladder removal in patients with acute cholecystitis. This study aims to enhance surgical outcomes and patient satisfaction.

Acute Cholecystitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOrthopedics and Traumatology

Prostate Cancer: HIFU and Hormone Therapy Study

We are testing a combination of high-intensity focused ultrasound and short-term hormone therapy for men with intermediate-risk localized prostate cancer. The goal is to see if this approach improves cancer control and maintains sexual and urinary functions.

Intermediate Risk Prostate Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

Heart Failure: Empagliflozin and Dapagliflozin Study

We are investigating how two medications may improve outcomes for patients hospitalized with acute heart failure. The study looks at their effects on heart function and other health indicators.

Acute Decompensated Heart Failure>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Erosive Esophagitis: Linaprazan Glurate vs. Lansoprazole

We are studying whether linaprazan glurate can heal erosive esophagitis in patients with GERD better than lansoprazole. This trial aims to evaluate the effectiveness and safety of the new treatment.

Erosive Esophagitis≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

BCG Vaccine for Radiologically Isolated Syndrome (RIS)

We are studying whether the BCG vaccine can help reduce new brain lesions in people diagnosed with Radiologically Isolated Syndrome. The trial also looks at the safety of the vaccine and other brain changes over time.

Radiologically Isolated Syndrome>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

SGLT-2 Inhibitors for Elderly Patients with Type 2 Diabetes

We are comparing different SGLT-2 inhibitors to see which helps elderly patients manage their blood sugar levels safely. The study looks at effectiveness and potential side effects over time.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDiabetologyEndocrinology

Narcolepsy and Idiopathic Hypersomnia: ORX750 Study

We are testing a new medication, ORX750, to see if it is safe and well-tolerated in people with narcolepsy and idiopathic hypersomnia. This study will help us understand how the drug works in the body.

Narcolepsy with CataplexyIdiopathic Hypersomnia3-6 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Colorectal Cancer: Galunisertib and Capecitabine Study

We are investigating a new drug combination for patients with advanced colorectal cancer that hasn't responded to chemotherapy. The goal is to learn more about its safety and effectiveness in treating this condition.

Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

TryptoBPH: Tryptophan for Benign Prostatic Hyperplasia

We are studying whether tryptophan can improve urinary symptoms in men with benign prostatic hyperplasia. The trial will also look at its effects on prostate size and quality of life.

Benign Prostatic Hyperplasia6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineUrology

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology